Anisotropine methylbromide is a quaternary ammonium compound. Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents. Depending on the dose, anisotropine methylbromide may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary bladder and may have a slight relaxant action on the bile ducts and gallbladder. In general, smaller doses of anisotropine methylbromide inhibit salivary and bronchial secretions, sweating, and accommodation; cause dilatation of the pupil; and increase the heart rate. Larger doses are required to decrease motility of the gastrointestinal and urinary tracts and to inhibit gastric acid secretion.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aclidinium | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Aclidinium. |
| Mianserin | Mianserin may increase the anticholinergic activities of Anisotropine methylbromide. |
| Mirabegron | The risk or severity of urinary retention can be increased when Anisotropine methylbromide is combined with Mirabegron. |
| Potassium chloride | The risk or severity of gastrointestinal ulceration can be increased when Anisotropine methylbromide is combined with Potassium chloride. |
| Pramlintide | The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Anisotropine methylbromide. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Anisotropine methylbromide. |
| Tiotropium | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Tiotropium. |
| Topiramate | The risk or severity of hyperthermia and oligohydrosis can be increased when Anisotropine methylbromide is combined with Topiramate. |
| Umeclidinium | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Umeclidinium. |
| Glycopyrronium | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Glycopyrronium. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Botulinum toxin type A. |
| Glucagon | Anisotropine methylbromide may increase the gastrointestinal motility reducing activities of Glucagon. |
| Sulpiride | Anisotropine methylbromide may increase the anticholinergic activities of Sulpiride. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Botulinum toxin type B. |
| Eluxadoline | The risk or severity of constipation can be increased when Anisotropine methylbromide is combined with Eluxadoline. |
| Ramosetron | The risk or severity of constipation can be increased when Anisotropine methylbromide is combined with Ramosetron. |
| Naltrexone | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Naltrexone. |
| Bezitramide | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Bezitramide. |
| Tramadol | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Tramadol. |
| Morphine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Morphine. |
| Codeine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Codeine. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Hydromorphone. |
| Methadone | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Methadone. |
| Meperidine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Meperidine. |
| Oxycodone | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Oxycodone. |
| Butorphanol | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Butorphanol. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Dextropropoxyphene. |
| Pentazocine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Pentazocine. |
| Sufentanil | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Sufentanil. |
| Alfentanil | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Alfentanil. |
| Fentanyl | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Fentanyl. |
| Nalbuphine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Nalbuphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Remifentanil. |
| Buprenorphine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Buprenorphine. |
| Hydrocodone | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Hydrocodone. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Diphenoxylate. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Oxymorphone. |
| Dezocine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Dezocine. |
| Levacetylmethadol | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Levacetylmethadol. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Diamorphine. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Ethylmorphine. |
| Etorphine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Dextromoramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Desomorphine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Carfentanil. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Dihydrocodeine. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Dihydromorphine. |
| Tapentadol | The risk or severity of urinary retention and constipation can be increased when Anisotropine methylbromide is combined with Tapentadol. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Ketobemidone. |
| DPDPE | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Lofentanil. |
| Opium | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Opium. |
| Normethadone | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Piritramide. |
| Alphaprodine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Alphaprodine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Nicomorphine. |
| Meptazinol | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Meptazinol. |
| Phenoperidine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Phenoperidine. |
| Phenazocine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Phenazocine. |
| Tilidine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Tilidine. |
| Carfentanil, C-11 | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Carfentanil, C-11. |
| Benzhydrocodone | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Benzhydrocodone. |
| Naloxegol | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Naloxegol. |
| Trospium | The risk or severity of adverse effects can be increased when Trospium is combined with Anisotropine methylbromide. |
| Oxyphenonium | The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Anisotropine methylbromide. |
| Benzatropine | The risk or severity of adverse effects can be increased when Benzatropine is combined with Anisotropine methylbromide. |
| Disopyramide | The risk or severity of adverse effects can be increased when Disopyramide is combined with Anisotropine methylbromide. |
| Metixene | The risk or severity of adverse effects can be increased when Metixene is combined with Anisotropine methylbromide. |
| Terfenadine | The risk or severity of adverse effects can be increased when Terfenadine is combined with Anisotropine methylbromide. |
| Buclizine | The risk or severity of adverse effects can be increased when Buclizine is combined with Anisotropine methylbromide. |
| Trihexyphenidyl | The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Anisotropine methylbromide. |
| Oxyphencyclimine | The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Anisotropine methylbromide. |
| Procyclidine | The risk or severity of adverse effects can be increased when Procyclidine is combined with Anisotropine methylbromide. |
| Hyoscyamine | The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Anisotropine methylbromide. |
| Methscopolamine bromide | The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Anisotropine methylbromide. |
| Darifenacin | The risk or severity of adverse effects can be increased when Darifenacin is combined with Anisotropine methylbromide. |
| Tridihexethyl | The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Anisotropine methylbromide. |
| Atropine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Atropine. |
| Nicardipine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Nicardipine. |
| Mecamylamine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Mecamylamine. |
| Pirenzepine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Pirenzepine. |
| Homatropine methylbromide | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Homatropine methylbromide. |
| Benzquinamide | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Benzquinamide. |
| Propantheline | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Propantheline. |
| Dicyclomine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Dicyclomine. |
| Tropicamide | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Tropicamide. |
| Cocaine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Cocaine. |
| Quinidine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Quinidine. |
| Amantadine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Amantadine. |
| Methantheline | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Methantheline. |
| Cycrimine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Cycrimine. |
| Cyclopentolate | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Cyclopentolate. |
| Tolterodine | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Tolterodine. |
| Oxybutynin | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Oxybutynin. |
| Pentolinium | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Pentolinium. |
| Trimethaphan | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Trimethaphan. |